Patients with haematological malignancies are at high risk of infection because of various
mechanisms of humoral and cell-mediated immune deficiencies, which mainly depend on …

Introduction: Multiple myeloma (MM) is characterized by notable inter-patient and intra-
clonal heterogeneity that is gradually decoded over the last decade. Despite the deeper and …

There are disparities in outcomes for patients with multiple myeloma (MM). We evaluated the
influence of sociodemographic factors on global disparities in outcomes for patients with …

Infections are a major cause of death in patients with multiple myeloma. A post hoc analysis
of the phase 3 FIRST trial was conducted to characterize treatment-emergent (TE) infections …

Objectives This study aimed to provide real‐world data on the characteristics and treatment
of patients with multiple myeloma (MM) at the time of death. Methods The study was a …

The frequency and causes of early mortality in patients with newly diagnosed multiple
myeloma (NDMM) have not been well described in the era of novel agents. We investigated …

Introduction Despite significant improvements in multiple myeloma (MM) treatment
modalities, patient mortality early in the course of disease has been identified as a persistent …

Background Infection is a leading cause of morbidity and death in patients with multiple
myeloma (MM). The increased susceptibility to infection is complicated and multifactorial …

Multiple myeloma is a heterogeneous disease with variable survival; this variability cannot
be fully explained by the current systems of risk stratification. Early mortality remains a …

Multiple myeloma is a cancer of the immune system. Infection is a major cause of morbidity
and mortality in patients with multiple myeloma. Some of these infections are preventable by …